Question 1

What is the analyst consensus rating for NAMS?

Accepted Answer

The analyst consensus rating for NAMS is "Buy" based on 3 analyst recommendations.

Question 2

What is the average price target for NAMS?

Accepted Answer

The average 12-month price target for NAMS is $44.67, representing an upside of 26.8% from the current price of $35.24.

Question 3

What do analyst ratings mean?

Accepted Answer

Analyst ratings indicate investment recommendations: Strong Buy and Buy are bullish signals suggesting the stock may outperform. Hold means the stock is fairly valued. Sell and Strong Sell are bearish signals suggesting potential underperformance. These ratings are based on fundamental analysis and valuation models.

Question 4

What is a price target?

Accepted Answer

A price target is an analyst's projection of a stock's fair value over a specific timeframe, typically 12 months. Analysts use fundamental analysis, financial modeling, and industry comparisons to estimate where the stock should trade. Price targets can range from low (conservative) to high (optimistic) estimates.

Date	Analyst	Firm	Action	Rating	Price Target
Jan 21, 2026	Leonid Timashev	RBC Capital	Maintains	Buy	$44.00 → $47.00 +3.00 (6.8%)
Dec 16, 2025	James Condulis	Stifel	Maintains	Strong Buy	$44.00 → $50.00 +6.00 (13.6%)
Dec 2, 2025	Asad Haider	Goldman Sachs	Maintains	Hold	$30.00 → $37.00 +7.00 (23.3%)

NewAmsterdam Pharma Company (NAMS) Stock Analyst Forecast

Analyst Consensus Rating

Consensus Rating

Average Price Target

Latest NAMS Analyst Ratings & Recommendations